新闻
Phase II Data in Treatment-Naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Demonstrates Best-in-Class Efficacy as Monotherapy
临床结果免疫疗法孤儿药上市批准
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
细胞疗法免疫疗法临床结果
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
临床结果孤儿药基因疗法临床研究
Juvena Therapeutics Announces Initiation of First-in-Human Clinical Trial of JUV-161
孤儿药
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
临床结果快速通道孤儿药
Axovia Therapeutics Unveils New Preclinical Data for AXV-201, for Treatment of Genetic Obesity Caused by MC4R Mutations, at ASGCT
孤儿药临床研究
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals
引进/卖出免疫疗法
临床结果优先审批
BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years
上市批准优先审批申请上市
BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders